Sign inJoin waitlistJoin the waitlist

John Wrangle

HART Scientific Director, MUSC Hollings Cancer Center · Medical University of South Carolina College of Medicine

Credentials: · · · ·

History

Hematology and Medical Oncology
2008–2011
Internal Medicine
2005–2008
Tulane University School of Medicine
2001–2005

Research

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2017 · 2,096 citations
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer
Cancer Discovery · 2011 · 515 citations
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
The Lancet Oncology · 2018 · First of 29 authors · 361 citations

MB
Malcolm Brock
8 papers
JH
James Herman
6 papers
Zihai Li
6 papers
Charles Rudin
5 papers
David Cole
4 papers
RJ
Rosalyn Juergens
4 papers
ST
Salina Tsai
3 papers
Vamsi Velcheti
3 papers
AS
Alexander Spira
2 papers
AD
Anastasios Dimou
2 papers · 2 as a fellow
Bruce Thiers
2 papers
CS
Carol Sherman
2 papers

Grants

Exploiting Lineage-Specific Dependencies in Solid Tumors: Using Transcription Factors to Drive Therapeutic Effect In Situ
National Cancer Institute · R21
Contact PI · $388.3K · Medical University of South Carolina
2024–2026
Lymphocyte and Inflammatory Cytokine Markers of Response in the First-in-Human Combination of Anti-PD-1 mAb and IL-15/IL-15Ra Complexes and Investigation of Mediators of Anti-Tumor Immune Responses
National Cancer Institute · R01
Contact PI · $2M · Medical University of South Carolina
2019–2025
MUSC/HCC Paul Calabresi Clinical Oncology Career Development Program
National Cancer Institute · K12
Contact PI · $1.3M · Medical University of South Carolina
2013–2024

Clinical trials

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Principal investigator · Active not recruiting · Phase 2, Phase 3
SWOG Cancer Research Network
2022–2027
ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer
Principal investigator · Completed · Phase 1, Phase 2
Medical University of South Carolina
2016–2023
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Site PI · Recruiting · Phase 2, Phase 3
SWOG Cancer Research Network
2019–2029